ASRT Assertio Holdings Inc.

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split

LAKE FOREST, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has filed a Certificate of Amendment to its certificate of incorporation (the “Certificate of Amendment”) to implement a one-to-four reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on May 18, 2021, and the Company’s common stock will begin trading on a split-adjusted basis when the market opens on May 18, 2021.

When the Reverse Split becomes effective, every four shares of the Company’s issued and outstanding common stock will automatically be converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments will be made to (i) the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock, (ii) the number of shares issuable upon the vesting of all restricted stock units and (iii) the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any fraction of a share of common stock that would be created as a result of the Reverse Split will be cashed out at a price equal to the product of the closing price of the Company’s common stock on May 17, 2021 and the amount of the fractional share.

The Company’s common stock will continue to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ASRT.” The new CUSIP number for the common stock following the Reverse Split will be 04546C 205.

Continental Stock Transfer & Trust, has been appointed by the Company to act as exchange agent for the Reverse Split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers’ particular processes. Holders of certificated shares will be contacted by the Company or its exchange agent with further details about how to surrender old certificates in exchange for new ones.

About Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions.

Investor Contact  

Max Nemmers

Head, Investor Relations and Administration



EN
17/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assertio Holdings Inc.

 PRESS RELEASE

Assertio Presents First-Ever Real-World Study Showing Patient Experien...

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LG...

 PRESS RELEASE

Assertio to Present New Data from Real-World Evidence Study of SYMPAZA...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commerci...

 PRESS RELEASE

Assertio to Participate in the HC Wainwright and Lake Street Conferenc...

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright repr...

 PRESS RELEASE

Assertio Reports Second Quarter 2025 Financial Results

Assertio Reports Second Quarter 2025 Financial Results Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the second quarter ended June 30, 2025. Said Brendan O...

 PRESS RELEASE

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Result...

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio’s management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company’s 2025 strategic plans. To access the live webcast, conference call inform...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch